Physician profile
Donna Ching
NPI 1780636670
$3,785.48
in general payments reported to CMS, 2019-2025
19 companies · $523 in 2025
The $523 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $311 · 2021: $884 · 2022: $881 · 2023: $383 · 2024: $330 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $827.46 | 2019-2025 | Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $567.43 | 2020-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $370.45 | 2022-2025 | Caplyta |
| Pfizer INC. | $336.43 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $306.44 | 2019-2022 | |
| Amgen INC. | $305.77 | 2020-2023 | Repatha, Otezla |
| Avanir Pharmaceuticals, INC. | $214.86 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $197.70 | 2019-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $147.74 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $122.74 | 2021 | |
| Lilly USA, LLC | $79.07 | 2022 | |
| Abbvie INC. | $69.47 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $64.44 | 2024 | Ingrezza |
| Lundbeck LLC | $49.09 | 2022 | |
| Arbor Pharmaceuticals, INC. | $39.51 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $28.79 | 2025 | Auvelity |
| Allergan, INC. | $22.81 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.37 | 2022 | |
| Biogen, INC. | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Ching listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.